Gene: CIPC
Official Full Name: CLOCK interacting pacemakerprovided by HGNC
Gene Summary: Predicted to be involved in negative regulation of DNA-templated transcription and negative regulation of circadian rhythm. Located in cytosol; nucleolus; and nucleoplasm. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO24211 | CIPC Knockout cell line (HeLa) | Human | CIPC | 1:3~1:6 | Negative | Online Inquiry |
KO24212 | CIPC Knockout cell line (HCT 116) | Human | CIPC | 1:2~1:4 | Negative | Online Inquiry |
KO24213 | CIPC Knockout cell line (HEK293) | Human | CIPC | 1:3~1:6 | Negative | Online Inquiry |
KO24214 | CIPC Knockout cell line (A549) | Human | CIPC | 1:3~1:4 | Negative | Online Inquiry |
CIPC Gene Knockout Cell Lines are meticulously engineered cellular models designed to facilitate the investigation of the CIPC gene's function in various biological processes. By utilizing CRISPR-Cas9 technology, these cell lines exhibit complete gene disruption, enabling researchers to study the phenotypic consequences of CIPC deficiency with precision. The knockout of this gene allows for a deeper understanding of its role in biological pathways, including cellular proliferation, apoptosis, and differentiation, ultimately relevant in diverse fields such as cancer research and regenerative biology.
The primary mechanism by which the CIPC Gene Knockout Cell Lines operate is through the targeted disruption of the CIPC gene, a critical regulator of cellular signaling pathways. This disruption yields a valuable tool for elucidating gene functions, offering insights into how the loss of CIPC expression affects cellular behavior and signaling cascades. Researchers can use these cell lines to model diseases where CIPC is implicated and to assess the efficacy of therapeutics aimed at modulating related pathways in various cancer types.
From a scientific standpoint, the CIPC Gene Knockout Cell Lines serve essential applications in both research and clinical settings. They allow for the investigation of gene function through loss-of-function studies, providing a clearer picture of gene interactions within complex networks. Furthermore, these cell lines can be leveraged in drug discovery endeavors, as they offer a platform to screen novel compounds in a CIPC-deficient environment, simulating pathological states.
Compared to alternative models such as siRNA knockdown systems or conventional knockout models, the CIPC Gene Knockout Cell Lines afford enhanced stability and reproducibility. With the CRISPR-Cas9 technology, these cell lines maintain stable genetic alterations over extended periods, thereby allowing for longitudinal studies without the variability introduced by transient methods.
For researchers and clinicians, the value of CIPC Gene Knockout Cell Lines lies in their ability to streamline experimental designs and foster discoveries in gene function and disease mechanisms. By providing a reliable and highly specific tool for research, we enable advancements that can lead to novel therapeutic strategies and improve our understanding of complex diseases.
Our company is committed to excellence in biotechnology, emphasizing precision and innovation in every product we offer. With expertise in developing high-quality biological research tools, we ensure that our CIPC Gene Knockout Cell Lines meet the rigorous demands of today’s researchers, supporting their quest for groundbreaking discoveries.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.